|
VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, RNASET2 may contribute to vitiligo pathogenesis by inhibiting TRAF2 expression and, as such, RNASET2 may represent a potential therapeutic target of vitiligo.
|
24457966 |
2014 |
|
Vitiligo
|
0.110 |
Biomarker
|
disease |
BEFREE |
Thus, RNASET2 may contribute to vitiligo pathogenesis by inhibiting TRAF2 expression and, as such, RNASET2 may represent a potential therapeutic target of vitiligo.
|
24457966 |
2014 |
|
Vitiligo
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants.
|
27723757 |
2016 |
|
Vitiligo
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC.
|
20526339 |
2010 |
|
Vitiligo
|
0.110 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC.
|
20526339 |
2010 |
|
Thyroid Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
RNASET2 tag SNP but not CCR6 polymorphisms is associated with autoimmune thyroid diseases in the Chinese Han population.
|
25928629 |
2015 |
|
Slow progression
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Ribonuclease T2 (RNASET2) and gametogenetin binding protein 2 (GGNBP2) are tumor suppressor genes whose expression is downregulated in ovarian and other types of cancer.
|
24842157 |
2014 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
RNASET2 as a tumor antagonizing gene in a melanoma cancer model.
|
18543608 |
2008 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Recently, RNaseT2 family members have been implicated in human pathologies such as cancer and parasitic diseases.
|
20189811 |
2010 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
In light of the widely recognized opposite roles of M1-like and M2-like macrophages on cancer growth, and our largely incomplete knowledge of the cellular and molecular mechanisms underlying the establishment of the M1-like versus M2-like balance within a tumor mass, we report here results from in vitro assays pointing at the human RNASET2 gene as a potential regulator of the balance between M1-like/M2-like macrophage polarization.
|
30218741 |
2018 |
|
Primary biliary cirrhosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Although no significant differences in clinical or biochemical characteristics between patients with PBC and PBC-AITD were seen (all P>0.05), liver function tests and metabolic traits in PBC patients were significantly (all P<0.05) affected by the CTLA4 (rs3087243), MMEL1 (rs2843403), PTPN22 (rs2476601) and RNASET2 (rs9355610) variants.
|
28922436 |
2017 |
|
Poor speech
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Parasitic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Recently, RNaseT2 family members have been implicated in human pathologies such as cancer and parasitic diseases.
|
20189811 |
2010 |
|
ovarian neoplasm
|
0.040 |
AlteredExpression
|
disease |
LHGDN |
Moreover, we have extended our previous studies by evaluating the effect of RNASET2 on the metastatic behavior of the highly-invasive ovarian cancer cell line HEY3MET2.
|
15809705 |
2005 |
|
ovarian neoplasm
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results further highlight the critical role played by the microenvironment in RNASET2-mediated ovarian tumor suppression, which could eventually contribute to better clarify the pathogenesis of this disease.
|
23630276 |
2013 |
|
ovarian neoplasm
|
0.040 |
Biomarker
|
disease |
BEFREE |
Analysis of 55 primary ovarian tumors and several ovarian tumor cell lines indicated that the RNASE6PL gene is not mutated in tumor tissues, but its expression is significantly reduced in 30% of primary ovarian tumors and in 75% of ovarian tumor cell lines.
|
11314033 |
2001 |
|
ovarian neoplasm
|
0.040 |
Biomarker
|
disease |
BEFREE |
The integrated results suggested that RNASET2 and GGNBP2 contributed to drug resistance in ovarian cancer, via direct or indirect interactions with a number of microRNAs, genes and proteins involved in a wide range of biological processes and pathways.
|
24842157 |
2014 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer.
|
24842157 |
2014 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We therefore propose that RNASE6PL may be a candidate for the 6q27 senescence inducing and class II tumor suppressor gene in ovarian cancer.
|
11314033 |
2001 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The RNASET2 gene was shown to behave as a class II tumor suppressor and abolish the tumorigenic potential of an ovarian cancer-derived cell line.
|
15809705 |
2005 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
RNASET2 as a tumor antagonizing gene in a melanoma cancer model.
|
18543608 |
2008 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In this aggressive group of cancers, which have highly deregulated proliferation pathways, RNASET2 fails to exert the growth-inhibiting effects described in other types of neoplasms.
|
29763721 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells.
|
21646684 |
2011 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
RNASET2 knockdown was shown to stimulate in vivo tumor growth early after microinjection of OVCAR3 cells in nude mice.
|
23630276 |
2013 |